Compare EVLV & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVLV | GHRS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 988.3M | 892.0M |
| IPO Year | N/A | 2021 |
| Metric | EVLV | GHRS |
|---|---|---|
| Price | $6.97 | $12.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $9.13 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 2.9M | 247.9K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $136,501,000.00 | N/A |
| Revenue This Year | $41.14 | N/A |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.16 | N/A |
| 52 Week Low | $2.64 | $6.72 |
| 52 Week High | $8.91 | $20.50 |
| Indicator | EVLV | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 39.07 |
| Support Level | $6.52 | $13.94 |
| Resistance Level | $6.78 | $15.00 |
| Average True Range (ATR) | 0.24 | 0.84 |
| MACD | 0.13 | -0.22 |
| Stochastic Oscillator | 80.58 | 3.83 |
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.